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a b s t r a c t
Macrophages play an important role in HIV/SIV pathogenesis by serving as a reservoir for viral
persistence in brain and other tissues. Infected macrophages have been detected in brain early after
infection, but macrophage-tropic viruses are rarely isolated until late-stage infection. Little is known
about early variants that establish persistent infection in brain. Here, we characterize a unique
macrophage-tropic SIV envelope glycoprotein (Env) variant from two weeks post-infection in blood of
an SIVmac251-infected macaque that is closely related to sequences in brain from animals with
neurological disease. SIVmac251 clones expressing this Env are highly fusogenic, and replicate efﬁciently
in T cells and macrophages. N173 and N481 were identiﬁed as novel determinants of macrophage
tropism and neutralization sensitivity. These results imply that macrophage-tropic SIV capable of
establishing viral reservoirs in brain can be present in blood during early infection. Furthermore, these
SIVmac251 clones will be useful for studies on pathogenesis, eradication, and vaccines.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Introduction
HIV and SIV infections are characterized by progressive CD4þ T
cell depletion and chronic immune activation, eventually leading to
immunodeﬁciency and AIDS. The main target cells infected by these
viruses are CD4þ T cells and macrophages. While CD4þ T cells are
progressively depleted by infection, macrophages are relatively
resistant to cytopathic effects of these viruses (Ho et al., 1986) and
serve as a reservoir for viral persistence in the central nervous system
(CNS) and other tissues including bone marrow, lymph node, spleen,
lung, and gut (Alexaki et al., 2008; Bissel et al., 2008; Clements et al.,
2002; Gorry et al., 2005; Heise et al., 1994, 1993; Igarashi et al., 2001;
Smith et al., 2003). Infection of macrophages in the brain also causes
neurological dysfunction and encephalitis, characterized by multi-
nucleated giant cells, reactive astrocytes, and white matter abnorm-
alities (Dunfee et al., 2006), and creates a sanctuary site for viral
persistence and development of drug resistance due to poor CNS
penetration of most anti-retroviral drugs (Gorry et al., 2005).
A major obstacle to studies on macrophage-related pathogenesis
in animal models is the lack of a pathogenic SIV clone that
reproducibly causes macrophage infection and CNS disease. The
pathogenic clone SIVmac239 causes immunodeﬁciency and AIDS in
non-human primate models (Kestler et al., 1990), but its tropism is
restricted to CD4þ T cells (Mori et al., 1992) so it rarely causes
neurological disease. SIVmac316, originally isolated from SIVmac239-
infected animals at late-stage infection, replicates efﬁciently in
monocyte-derived macrophages (MDM) in vitro (Mori et al., 1992)
and induces AIDS in a subset of infected macaques (Johnson et al.,
2009). However, infected macrophages and macrophage-associated
pathology are rarely detected in SIVmac316-infected macaques
(Borda et al., 2004; Johnson et al., 2009, 2003a; Kodama et al.,
1993). SIVmac251, a strain that replicates well in both CD4þ T cells
and macrophages, is frequently used for HIV/AIDS pathogenesis
studies in non-human primate models (Daniel et al., 1985; Kanki et
al., 1985; Letvin et al., 1985; Miller et al., 1998). However, the
composition of the swarm in this strain varies considerably after
ampliﬁcation in cell culture (Del Prete et al., 2013; Strickland et al.,
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2011), resulting in heterogeneous clinical outcomes and hindering
studies of viral determinants important for pathogenesis and immune
evasion. Viruses encoded by SIVmac251-derived molecular clones,
including SIVmac251BK28 (Kornfeld et al., 1987), SIVmac251 clone (Choi
et al., 1994; Naidu et al., 1988), SIVmac1A11 (Luciw et al., 1992), and
SIVmac32H (Rud et al., 1994), have been inoculated into animals, but
caused little or no disease in vivo. The uncloned SIVmac251 strain
commonly used for pathogenesis and vaccine studies consists of
more than 20 distinct env sequences; three env clones from this
swarm mediated viral replication in alveolar macrophages in vitro
(Bixby et al., 2010), but levels of replicationwere very low compared to
SIVmac316 (Bixby et al., 2010). The availability of pathogenic molecular
clones of SIVmac251 would facilitate development of animal models
to study macrophage-related pathogenesis and might also be useful as
a challenge strain for vaccine studies.
HIV/SIV macrophage tropism is determined primarily by the viral
envelope glycoproteins (Env). The Env gp120 external subunit is non-
covalently linked to the gp41 transmembrane subunit, and organized
as trimers on the viral membrane. gp120 binding to CD4 induces
conformational changes that expose the CCR5 coreceptor binding site
and enable gp120-CCR5 binding, which triggers additional conforma-
tional changes that lead to fusion and viral entry. The gp120 V1–V3
variable regions play important roles in mediating interactions with
CD4 and CCR5. The V3 loop and bridging sheet region constitute the
CCR5 binding site. The V1/V2 loop inﬂuences gp120 binding to CD4/
CCR5 by partially occluding receptor binding sites in the unliganded
structure (Johnson et al., 2003b; Pinter et al., 2004; Sullivan et al.,
1998; Wyatt et al., 1995). Structural models of Env trimers suggest that
the V1/V2 loop interacts with the V3 loop in the same or neighboring
gp120 protomer (Chen et al., 2005b; Kwong et al., 2000; Liu et al.,
2011; Rusert et al., 2011), an interaction that may inﬂuence CCR5
binding by affecting V3 loop orientation. Macrophage-tropic strains
overcome the entry restriction imposed by low CD4 expression on
macrophages via an enhanced capacity to mediate fusion and infection
at low CD4 levels (Bannert et al., 2000; Gorry et al., 2002; Mori et al.,
2000). However, structural changes that enhance gp120 interaction
with CD4 often render macrophage-tropic viruses more susceptible
to antibody recognition (Dunfee et al., 2009; Dunfee et al., 2007;
Means et al., 2001; Musich et al., 2011; Puffer et al., 2002). Consistent
with these ﬁndings, most macrophage-tropic SIV clones are highly
neutralization sensitive. Together with previous studies suggesting
that most transmitted/founder viruses replicate poorly in macro-
phages (Isaacman-Beck et al., 2009; King et al., 2013; Li et al., 2010;
Ochsenbauer et al., 2012; Salazar-Gonzalez et al., 2009), these ﬁndings
led to the prevailing view that macrophage-tropic HIV/SIV variants are
rare or absent during early-stage infection.
HIV and SIV are genetically compartmentalized in the CNS due to
founder effects and independent viral evolution, reﬂecting differences
in target cells (i.e., macrophages) and immune selection pressures.
Although viruses enter the brain within weeks after primary infection,
infection usually remains latent until late-stage disease. Here, we
identify a macrophage-tropic SIVmac251 variant in blood at two
weeks post-infection that shares high sequence identity with gp120
sequences in the brain of animals with rapid disease progression and
SIV encephalitis (SIVE). Infectious molecular clones encoding gp120
sequences from this early variant showed high fusion activity, and
mediated high levels of viral replication and multinucleated giant cell
formation in macrophages. Two N-linked glycosylation sites in the V2
and C5 regions were identiﬁed as determinants of macrophage
tropism and neutralization sensitivity. These results suggest that
macrophage-tropic SIV variants capable of establishing persistent viral
reservoirs in macrophages in the CNS and other tissues can be present
in blood during early infection. These SIVmac251 replication-
competent molecular clones will be useful for future studies on
macrophage-related pathogenesis and approaches to eradicate viral
reservoirs in brain and other tissues.
Results
Identiﬁcation of a macrophage-tropic SIV variant in blood during
early infection
To identify macrophage-tropic SIV viruses in blood during early
infection of rhesus macaques, we analyzed unpublished SIV gp120
sequences generated in previous studies (Orandle et al., 2002;
Table 1
Clinical and pathological ﬁndings in SIVmac251-infected rhesus macaques.
Group Animal Inoculum Survival
dpia
AIDS Pathology Reference
I 147-94 SIVmac251 (0.032 ng p27, i.v.b) 70 Yes Escherichia coli enteritis, Enterocytozoon bieneusi
cholecystitis, lymphoid depletion
Current
publication
168-94 SIVmac251 (0.032 ng p27, i.v.) 856 Yes Severe intestinal mycobacteriosis, peritonitis,
lymphoid depletion
Current
publication
90-95 SIVmac251 (24 ng p27, vag.c) 122 Yes SIV giant cell pneumonia, adenovirus, CMV, candidiasis Current
publication
166-95 SIVmac251 (24 ng p27, vag.) 463 Yes SIV pulmonary arteriopathy, pericarditis, myocarditis, and sepsis due to
Staphylococcus aureus
Current
publication
II A92-620 SIVmac251 (20 ng p27, i.v.) 115 Yes SIVEd (MNGCe); CMV pneumonia; severe segmental purulent enteritis
and peritonitis and lymphangiectasia
Williams
et al. (2002)
A95-346 SIVmac251 (20 ng p27, i.v.) 190 Yes SIVE (MNGC); giant cell pneumonia; giant cell enteritis Williams
et al. (2001)
A97-6 SIVmac251 (20 ng p27, i.v.) 243 Yes SIVE (MNGC); severe chronic active gastritis; Severe AIDS encephalopathy,
brain & spinal cord; Severe diffuse glomerulonephritis; Cirrhosis; Enterocytozoon
bieneusi, bile duct duodenum; Proliferative and ﬁbrinous peritonitis; Giant cell
pneumonia
Williams
et al. (2001,
2002)
A97-251 SIVmac251 (20 ng p27, i.v.) 233 Yes SIVE (MNGC); Pneumocystis carinii pneumonia (PCP); CMVf orchitis Orandle
et al. (2002)
a dpi, days post-infection.
b i.v., intravenous inoculation.
c vag., vaginal inoculation.
d SIVE, SIV encephalitis.
e MNGC, Multinucleated giant cells.
f CMV, Cytomegalovirus.
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Williams et al., 2002, 2001). We reasoned that these viruses could
be found using a sequence-based approach to search for gp120
sequences in blood at two weeks post-infection that share high
sequence identity with late-stage variants in brain from macaques
with SIVE. Early variants were ampliﬁed from PBMC genomic DNA
at two weeks post-infection from four SIVmac251-infected rhesus
macaques (Group I in Table 1). Late variants were ampliﬁed from
autopsy brain, lymph node, and bone marrow from a second group of
four SIVmac251-infected rhesus macaques that progressed rapidly to
AIDS, developed SIVE, and died within 8 months (Group II in Table 1).
Among early variants, desiv147c#4 had the closest relationship to the
gp120 consensus sequence in brain based on genetic distance (Fig. 1A).
desiv147c#4 shared 498% sequence identity with the gp120 con-
sensus sequence in brain and the brain variant most similar to this
consensus sequence (A92-620BR2). Furthermore, desiv147c#4 was
one of only two early variants in blood that clustered with late variants
in brain in phylogenetic analysis (Fig. 1B). Based on its high sequence
identity with gp120 sequences in brain, we predicted that desiv147c#4
is a macrophage-tropic Env.
Compared to published SIV sequences, desiv147c#4 is genetically
unique based on BLAST searches of sequences in the NCBI database.
desiv147c#4, A92-620BR2, and the gp120 consensus sequence in brain
were genetically distinct from a lab-adapted non-pathogenic SIV-
mac251 clone (Edmonson et al., 1998; Hoxie et al., 1988; Kornfeld
et al., 1987), with most differences mapping to the V1–V3 and C3
regions (Fig. 2). Sequence variation in these regions can inﬂuence Env
interactions with CD4/CCR5 (Chen et al., 2005b; Huang et al., 2005;
Johnson et al., 2002; Means et al., 2001; Rizzuto et al., 1998) and
thereby inﬂuence macrophage-tropism (Means et al., 2001; Mori et al.,
1992; Musich et al., 2011). The G384R change in C3 (corresponding to
G382R in other well-characterized SIV strains), at the N-terminus of
the conserved GGPDE domain in the CD4 binding loop (Chen et al.,
2005b), has been associated with macrophage-tropism and decreased
CD4 dependence in macrophage-tropic strains SIVmac316 and SIV/
17E-Fr (Flaherty et al., 1997; Mori et al., 1992, 2000; Otto et al., 2003).
V1–V3, and C3 sequences of desiv147c#4 were predominant in brain
and bone marrow, and frequent in lymph node (Table 2). This tissue
distribution suggests these gp120 sequences can support viral replica-
tion in tissues where macrophages (i.e., brain and bone marrow) as
well as T cells (i.e., lymph node) are the predominant target cells.
Viruses expressing V2 and C3 sequences from desiv147c#4 have
enhanced fusion activity and viral infectivity
To characterize phenotypes of SIV expressing V1–V3 and C3
variants from desiv147c#4 (Table 2), we made recombinant Envs
and infectious molecular clones (Fig. 3). The recombinant Envs were
expressed at similar levels in 293T cells (Fig. 4A). In fusion assays, the
239/251 V1–V3, and C3 Envs mediated higher levels of cell–cell fusion
with cells expressing low or high rhesus CD4 compared to the parental
Env (Fig. 4B). Next, we tested full-length replication-competent viruses
expressing these Envs in infection assays using TZM-BL cells, which
express high levels of human CD4 and CCR5. In these assays, 239/251
V2 and 239/251 C3 showed enhanced viral infectivity compared to the
parental 239/251 virus (po0.05) (Fig. 4C), whereas introducing the V1
and V3 variants reduced viral infectivity. The infectivity of 239/251 V1
was greatly impaired (po0.01) (Fig. 4C). These results show that
recombinant SIV 239/251 clones expressing V1–V3, and C3 sequences
from desiv147c#4 have high fusion activity, but different levels of viral
infectivity in TZM-BL cell assays.
N173 and N481 decrease fusion activity but enhance viral infectivity
Next, we constructed a panel of infectious molecular clones
expressing the V1–V3, and C3 variant sequences in different combina-
tions. In addition to these variants, we examined two additional amino
acid changes, T173N and S481N, which map to the V2 and C5 regions,
respectively. Although these potential N-linked glycosylation sites
(NXS/T) are highly conserved among SIV strains, they are absent in
the parental SIVmac251 clone used for experiments described above
(Fig. 2). When mapped to the unliganded SIV gp120 structure (Chen
et al., 2005a), N173 is located in the V1/V2 loop and N481 is located
near the CD4 binding loop (Fig. 5). Introducing N173 and N481 into
239/251 Envs did not have a signiﬁcant effect on Env expression or
gp160 processing to gp120 and gp41; a mobility shift was observed for
the gp160 and gp120 bands, consistent with addition of glycans at
these sites (Fig. 6A).
Next, we tested desiv147c#4 and 239/251 Envs and replica-
tion-competent viruses in fusion and infectivity assays. The
desiv147c#4 Env mediated high levels of cell–cell fusion and
showed similar viral infectivity as SIVmac316, a prototype
macrophage-tropic clone used as a positive control (Fig. 6B and
C). 239/251 V2C3 and V2V3C3 Envs had increased fusion activity
compared to the parental 239/251 (Fig. 6B). The high levels of
fusion mediated by 239/251 V2V3C3 Env were similar to those of
desiv147c#4 and SIVmac316 Envs, and were observed with cells
expressing either low or high levels of rhesus CD4. Introduction of
N173 and N481 reduced fusion activity of 239/251 Envs (Fig. 6B),
but enhanced viral infectivity in TZM-BL cells by 2.5- to 10-fold
(Fig. 6C). These results indicate that desiv147c#4 and 239/251
V2V3C3 Envs are highly fusogenic, similar to the macrophage-
tropic SIVmac316 Env, and that introducing N173 and N481 into
239/251 Envs reduces fusion activity, but enhances viral infectivity.
N173 and N481 decrease SIV replication in macrophages
Next, we examined the ability of viruses produced from recombi-
nant infectious molecular clones to replicate in primary rhesus
macaque PBMC and MDM. SIVmac239 and SIVmac316 were included
as controls. SIVmac239 replicates well in PBMC, but poorly in MDM,
whereas SIVmac316 replicates well in both cell types. The 239/251
viruses replicated efﬁciently in PBMC, with similar replication curves
and p27 peak titers (Fig. 7A). desiv147c#4 also replicated in PBMC, but
with delayed kinetics and slightly lower peak levels compared to the
other viruses (Fig. 7A). The same batch of virus stocks exhibited a
different pattern when tested for viral replication in MDM (Fig. 7B).
desiv147c#4, 239/251 WT, V2C3, and V1V2V3C3 replicated efﬁciently
with similar kinetics, whereas 239/251 V2V3C3 replicated poorly.
Adding N173 and N481 to the 239/251 recombinant viruses
reduced replication of these viruses in MDM (Fig. 7B). Multi-
nucleated giant cells (MNGC) were observed in macrophage
cultures infected with SIVmac316, desiv147#4, 239/251 WT, and
239/251 V2C3 (Fig. 8). MNGC induced by 239/251 V2C3 were
larger than those induced by 239/251 WT, but smaller than those
induced by SIVmac316 and desiv147c#4. These results suggest
that desiv147c#4 is a macrophage-tropic Env that can mediate
high levels of replication and MNGC formation in primary
macrophages. Furthermore, these phenotypes can be enhanced
by desiv147c#4 amino acid variants mapping to the V2 and C3
regions, but are inhibited by N173 and N481.
N173 and N481 enhance neutralization resistance
SIV macrophage tropism has been associated with high neu-
tralization sensitivity, which renders macrophage-tropic SIV
clones more susceptible to humoral immune responses. The V1/
V2 and V3 loops are targets for neutralizing antibodies, and
mutations in these regions can alter neutralization sensitivity
(Johnson et al., 2002; Means et al., 2001; Musich et al., 2011;
Pantophlet and Burton, 2006). To investigate whether the Env
sequences characterized in the preceding experiments alter
neutralization sensitivity, we tested recombinant viruses in a
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Fig. 1. Identiﬁcation of an early SIV variant in blood closely related to late variants in brain from macaques with SIV encephalitis. (A) Genetic distance between early variants
in blood from four macaques at two weeks post-infection and the gp120 consensus sequence of late variants in brain from four other macaques that developed rapid disease
progression and SIV. Among seven early variants, desiv147c#4 had the lowest genetic distance to the gp120 consensus sequence in brain, indicating highest genetic
similarity. (B) Phylogenetic analysis shows clustering of desiv147c#4 with sequences from brain (BR), bone marrow (BM), and lymph node (LN) tissues at autopsy from four
macaques that died with AIDS. Clones from early infection are colored in cyan. Clones from late infection are colored based on the animal from which they were derived.
Scale bar represents 0.01 nucleotide substitutions per base.
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neutralization assay. SIVmac239, a highly neutralization resistant
clone, and SIVmac316, a highly neutralization sensitive clone, were
included as controls. desiv147c#4 was highly sensitive to SIV-
mac251 and SIVmac239 antiserum (Table 3). Introducing amino
acid variants from the V2, V3 and C3 regions of desiv147c#4 into
SIV239/251 had no signiﬁcant effects on neutralization sensitivity.
In contrast, adding N173 and N481 strongly enhanced neutraliza-
tion resistance of the recombinant viruses to SIVmac251 and
Fig. 2. gp120 sequence differences between desiv147c#4 and a lab-adapted SIVmac251 clone map primarily to the V1, V2, V3 and C3 regions. Alignment of the gp120
consensus sequence in brain tissue from four macaques obtained at autopsy (Table 1), desiv147c#4, and A92-620BR2 (the brain variant most similar to the brain consensus
sequence) with the lab-adapted SIVmac251 gp120 sequence. Amino acid variants in the V1–V3 and C3 regions are highlighted. N-linked glycosylation sites are marked
with Ψ.
Table 2
desiv147c#4 sequences in the V1–V3, and C3 regions (shown in bold) match the predominant sequences in brain, bone marrow, and lymph node at late-stage infection.
Regions Residue no. Sequence Late infectiona Early infectionb
Total Brain Bone marrow Lymph node Total
% (n¼37) % (n¼13) % (n¼12) % (n¼12) % (n¼7)
V1 134–143 PTTPNTTSTK 35 38 42 25 14
PTSAPVSEK 35 8 42 58 14
PTAPTAASK 16 23 17 8 0
STTPKTISTK 5 15 0 0 0
PTTPSTTSTK 3 8 0 0 0
PTAPTAAPK 3 0 0 8 0
PPSAPASEP 3 8 0 0 0
V2 155–157 VHD 41 54 42 25 29
AQN 24 0 42 33 14
THD 24 31 17 25 57
AHN 3 8 0 0 0
AHD 3 0 0 8 0
IHD 3 8 0 0 0
AQD 3 0 0 8 0
V3 337 V 100 100 100 100 100
339 E 76 100 58 67 67
D 24 0 42 33 33
342 N 100 100 100 100 100
C3 384 R 100 100 100 100 100
a Clones from late infection were derived from autopsy brain, bone marrow, or lymph node tissue samples from four macaques that died with AIDS (Table 1).
b Clones from early infection were derived from PBMC two weeks post-infection from four macaques infected with uncloned SIVmac251virus stock (Table 1).
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SIVmac239 antiserum (Table 3). 239/251 WT NN and 239/251
V2C3 NN were highly resistant to both antisera. Next, we used
monoclonal antibodies targeting speciﬁc epitopes to probe struc-
tural changes. Antibodies 5B11, 7D3, and 36D5 target the CD4
binding site, CCR5 binding site, and V3 loop, respectively (Edinger
et al., 2000). Viruses expressing N173 and N481 exhibited
enhanced resistance to all three antibodies compared to those
lacking these N-glycosylation sites (Table 3). Thus, N173 and N481
enhance neutralization resistance of SIV239/251 recombinant
viruses, possibly through modulating accessibility of gp120 epi-
topes that overlap the CD4 and CCR5 binding sites.
To investigate relationships between neutralization sensitivity and
macrophage tropism, we performed Spearman correlation analysis.
Replication of SIV recombinant viruses in MDM was associated with
higher neutralization sensitivity to SIV251 antiserum (r¼0.7246,
p¼0.0117), SIV239 antiserum (r¼0.7356, p¼0.0099), 36D5 (anti-V3)
(r¼0.6416, p¼0.0333), and 5B11 (anti-CD4 binding site) (r¼0.5703,
p¼0.0669) (Fig. 9). Together, these results suggest that the ability of
these recombinant SIV clones to replicate in macrophages is associated
with higher overall neutralization sensitivity and increased exposure
of epitopes that overlap the CD4 binding site and V3 region.
239/251 Viruses with N173 and N481 are more neutralization
resistant when generated in PBMC compared to 293T cells
HIV/SIV gp160 processing and N-linked glycosylation are cell-
type dependent, which in part explains differences viral infectivity
and neutralization sensitivity when viruses are produced in
different cell types (Lin et al., 2003; Louder et al., 2005; Sawyer
et al., 1994; Tremblay et al., 1998; Willey et al., 1996). The
replication-competent viruses used in the experiments described
above were generated in 293T cells transfected with full-length
proviral DNA. To examine phenotypes of viruses generated in a
more relevant cell type, we tested viruses generated in PBMC.
PBMC-generated viruses used for these experiments were more
infectious than the corresponding 293T-generated viruses based
on infection of TZM-BL cells (0.1 ng of PBMC-derived virus stock
induced comparable levels of infection as those induced by 10 ng
of 293T-derived virus stock in TZM-BL cell assays), and induced
more severe cytopathic effects in TZM-BL cells at lower doses of
virus (data not shown). PBMC-generated viruses replicated as
efﬁciently as 293T cell-derived viruses in PBMC (Fig. 10A). Similar
to experiments described above (Fig. 7), PBMC-generated
desiv147c#4 replicated at moderate levels in MDM, while 239/
251 viruses with N173 and N481 replicated at low levels in MDM
(Fig. 10B). PBMC-generated 239/251 viruses without N173 and
N481 (WT and V2C3) were highly neutralization sensitive, similar
to those generated in 293T cells. However, 239/251 viruses con-
taining N173 and N481 (WT NN and V2C3 NN) were more
neutralization resistant when generated in PBMC, with one to
three logs difference in IC50 compared to the corresponding 293T-
derived viruses (Table 4). These results suggest that viruses
generated in PBMC were more infectious and neutralization
resistant compared to those generated in cell lines, but their cell
tropism was not changed.
Discussion
In this study, we identiﬁed a unique macrophage-tropic SIV-
mac251 early variant (desiv147c#4) in blood that shares high
sequence homology with the gp120 consensus sequence in brain
of animals that developed neurological disease. SIV251 clones
expressing desiv147c#4 gp120, or V2 and C3 variants from this
Fig. 3. Construction of full-length recombinant SIV 239/251 proviruses expressing gp120 sequences from the early variant desiv147c#4. The gp120 region and N-terminus of
gp41 of SIVmac251 was cloned into the full-length SIVmac239 provirus. Sequences in the V1, V2, V3 and C3 regions of desiv147c#4 were introduced into SIVmac251 gp120 to
create recombinant viruses.
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early variant, mediated high levels of fusion, replicated efﬁciently
in rhesus PBMC and macrophages, and induced MNGC formation
during infection of macrophages. The N-linked glycosylation sites
N173 in the V2 region and N481 in the C5 region were identiﬁed as
novel determinants of macrophage tropism and neutralization sensi-
tivity. These N-glycosylation sites reduced fusion activity and macro-
phage tropism, but enhanced viral infectivity and neutralization
resistance when introduced into SIVmac251. Together, these results
Fig. 4. SIV Envs expressing sequences from desiv147c#4 mediate high levels of cell–cell fusion but variable infection of TZM-BL cells. (A) Expression of recombinant Envs in
transfected 293T cells examined by western blot. (B) Cell–cell fusion assay. 293T cells transfected with GFP (negative control) or the indicated Env-expressing plasmids were
mixed with Cf2-luc cells expressing rhesus CCR5 and low or high levels of rhesus CD4 after transfection with CCR5 and either 0.5 or 10 mg CD4 plasmid DNA, respectively.
Cell–cell fusion was quantiﬁed by measuring luciferase activity. (C) Infection of TZM-BL cells with the indicated replication-competent SIV viruses (10 ng of p27). Shown are
means and standard deviation of samples from duplicate wells. n Indicates signiﬁcant difference vs. 239/251 WT (Student's t-test; po0.05). nn Indicates signiﬁcant difference
vs. 239/251 WT (po0.01). Shown are representative results of 3 to 6 independent experiments.
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suggest that desiv147c#4 may be a prototype for SIV strains that can
establish early infection of macrophages in brain and other
macrophage-rich tissues such as bone marrow, lung, and gut, and
induce macrophage-associated pathogenesis in vivo. desiv147c#4
includes sequences similar to those in bone marrow and lymph node,
suggesting this variant is not brain-speciﬁc. Compared to the well-
studied macrophage-tropic SIVmac316 Env, unique features of this
novel SIVmac251 variant include its isolation from early stage infec-
tion, close genetic relationship to sequences in brain from animals
with encephalitis, and lower neutralization sensitivity. Together, these
ﬁndings suggest that the infectious SIV clones expressing desiv147c#4
and other Envs described in the present study will be useful for future
studies on HIV/SIV pathogenesis.
Based on sequence analysis, desiv147c#4 represents a minor
variant in blood from SIVmac251-infected rhesus macaques at two
weeks post-infection. The low prevalence of macrophage-tropic
SIV variants in blood at early infection may in part be due to the
low frequency of these variants in the original SIVmac251 inocu-
lum. Consistent with this idea, only three of twenty Envs in a
SIVmac251 virus stock mediated signiﬁcant levels of viral replica-
tion in macrophages in a previous study (Bixby et al., 2010). gp120
Sequences in the present study were generated by bulk PCR from
previous animal studies using different virus stocks and inocula-
tion routes. Two macaques were infected with SIVmac251 stock
from one lab, and six were infected with SIVmac251stock from
another lab (Table 1). Despite the limitation of bulk PCR due to
potential template switching and recombination during ampliﬁca-
tion, as well as differences in virus stock origin, dose, and
inoculation route, we found high sequence identity between
desiv147c#4 and late variants in brain from four animals. How-
ever, we have not proven that desiv147c#4 is infecting the brain
and inducing SIVE. Furthermore, there are many variables in
animal models that cannot be predicted by in vitro studies.
Therefore, our conclusions must be restricted to those that can
be reached based on the present in vitro studies. Similar to previously
reported brain-derived SIV clones, including the macrophage-tropic
neurovirulent clone SIV/17E-Fr (Flaherty et al., 1997; Gaskill et al.,
2005; Puffer et al., 2002), SIV expressing desiv147c#4 replicates well in
both rhesus T cells and macrophages, suggesting it is replication-
competent in relevant target cells. Based on high similarity between
desiv147c#4 and brain-derived sequences together with functional
studies demonstrating that desiv147c#4 mediates high levels of fusion
and spreading infection in rhesus macrophages in vitro, we predict
that desiv147c#4 will be able to infect macrophages in brain and other
tissues in vivo. Future in vivo studies in an animal model will be
important to determine if this prediction is valid.
The monkey from which desiv147c#4 was isolated developed
AIDS and died by 70 days post-infection, a relatively rapid disease
course. As such, we cannot rule out the possibility that
desiv147c#4 was selected because the animal was immunocom-
promised due to rapid disease. Consistent with this possibility,
another animal model uses a macrophage-tropic clone, SIV/17E-Fr,
together with an immunosuppressive virus, SIV/DeltaB670, to induce
SIV-associated neurological disease (Zink et al., 1999), suggesting that
an immunocompromised environment may help to allow
macrophage-tropic SIV to induce pathogenesis in vivo. These ﬁndings
are consistent with the observation that macrophage-tropic variants
are present and can be detected at early infection in some HIV-
infected patients (Fiore et al., 1994; Schuitemaker et al., 1992;
Schuitemaker et al., 1991; Zhu et al., 1993), but usually do not emerge
until late infection, when the host immune system is compromised.
desiv147c#4 is genetically unique compared to published
sequences in the NCBI database. The V1–V3 sequences (Table 2)
are present in some transmitted/founder viruses or SIVmac251
swarm-derived molecular clones described by others (Del Prete
et al., 2013; Keele et al., 2009; Strickland et al., 2011), but these
sequences have not been previously associated with macrophage
tropism. Among published sequences, the one most closely related
to desiv147c#4 is a sequence isolated from a SIVmac251 stock,
251-PM, by Del Prete et al. (2013). The sequence, AGG38406.1,
shares 98% sequence identity (484 of 492 amino acids in gp120)
with desiv147c#4, and contains the V1–V3 and C3 sequences
characterized in the present study. The 8 amino acid differences
between desiv147c#4 and AGG38406.1 are E50D, D79E, I215L,
G327E, V416L, N418T, G426R, and a P142 insertion in the V1
region. 251-PM was generated by infecting CEMx174 cells, and is
genetically distinct from other SIVmac251 stocks, with 1.5% max-
imum sequence diversity within the swarm. No other features of
this SIVmac251 stock or clone were characterized in the study
(Del Prete et al., 2013). Most transmitted/founder HIV/SIV viruses
have been derived from individuals or animals infected through
mucosal routes, whereas desiv147c#4 was derived after intrave-
nous (i.v.) infection. Viruses transmitted via the i.v. route undergo
less stringent strain selection compared to mucosal transmission,
but viruses still encounter substantial selection pressure. While
most cases of mucosal transmission have only one transmitted/
founder virus, a prior study found that three of ﬁve animals
infected with uncloned SIVmac251 or SIVsmE660 quasispecies
through the i.v. route had four or fewer transmitted/founder
viruses (Keele et al., 2009). Accordingly, viruses transmitted
through the i.v. route may exhibit different phenotypes compared
to those through the mucosal route. desiv147c#4 replicates
efﬁciently in CD4þ T cells, the ﬁrst cell type infected after viruses
cross the mucosal barrier (Keele and Estes, 2011). As such, future
in vivo studies will be of interest to test whether desiv147c#4 can
mediate mucosal transmission.
Introducing desiv147c#4 gp120, or its V2 and C3 sequences, into
SIV 239/251 viruses had little or no effect on viral replication in MDM,
but enhanced fusion and MNGC formation in macrophages, an
important feature of SIV encephalitis. 239/251 Envs with these V2
and C3 sequences were able to mediate high levels of fusion with cells
expressing low or high CD4. V2 plays a role in gp120 interactions with
CCR5, and may thereby modulate fusion activity (Rizzuto et al., 1998;
Sullivan et al., 1998; Wyatt et al., 1995). Enhanced fusion activity of
239/251 V2 Envs might reﬂect structural changes involving the V2
region that lower CD4 dependence. G384R in the C3 region, ﬂanking
the conserved CD4 binding motif, GGDPE at the N-terminus, was
Fig. 5. N173 and N481 mapped onto the unliganded SIV structure published by
Chen et al. (2005b). N173 (shown as Ψ) is in the V1/V2 loop, which is absent in the
structure, shown here as a dashed line. N481 and CD4 binding loop containing the
conserved GGDPE domain are marked in gray. In this model, the N481
N-glycosylation site is located near the CD4 binding loop.
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previously identiﬁed as a determinant of macrophage-tropism and
low CD4 dependence (Mori et al., 1992, 2000; Otto et al., 2003;
Ryzhova et al., 2009). In these studies, G to R mutation of the ﬁrst
glycine in the GGDPE domain also showed CD4 independence, and
was associated with clones from brain, but not spleen (Ryzhova et al.,
2002b). Unexpectedly, this G to R mutation impaired gp120 binding to
CD4 by increasing the dissociation rate constant (koff) (Ryzhova et al.,
2002a), raising the possibility that mutations in this region may
facilitate Env-mediated fusion with low CD4 expressing cells by
facilitating interaction with CCR5 rather than CD4. These ﬁndings also
suggest a close association between cell and cell fusion activity with
target cells expressing low CD4 and MNGC induction in macrophages,
phenotypes likely to be important for cell–cell transmission and viral
pathogenicity in vivo.
Unexpectedly, the N-linked glycosylation sites N173 and N481
were identiﬁed as determinants of viral infectivity and macro-
phage tropism. These two N-glycosylation sites are highly con-
served among SIV strains, but missing in the SIVmac251BK28 clone,
possibly due to prolonged passage in tissue culture. Notably, they
were restored when SIVmac251BK28 was introduced into animals
Fig. 6. N173 and N481 N-glycosylation sites inﬂuence cell–cell fusion and viral infectivity in TZM-BL cells. Env expression was examined by western blot (A). Fusion assays
using Env clones (B) and TZM-BL infection assays using replication-competent viruses (C) were performed as described in Fig. 4. Introduction of N173 and N481 into
SIVmac251 gp120 (indicated as NN) reduces Env fusion activity, but enhances viral infectivity in TZM-BL assays. Shown are mean and standard deviation of samples from
duplicate wells. n Indicates signiﬁcant differences by Student's t-test (po0.05). Shown are representative results of one to ﬁve independent experiments.
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Fig. 7. Replication of recombinant SIV viruses in primary rhesus macaque PBMC (A) and MDM (B). Viral replication was quantiﬁed in culture supernatants from PBMC and
MDM cultures infected with the indicated virus stocks (10 ng of p27) by measuring the concentration of SIV p27 antigen in cell culture supernatants by ELISA at the indicated
time points. Introduction of N173 and N481 into SIVmac251 gp120 (indicated as NN) reduced viral replication in macrophages, while not affecting viral replication in PBMC.
Shown are means of samples from duplicate wells. Data in each panel are from a single experiment, with viral replication of the panel of mutants examined in cells from the
same animal donor. Shown are representative results of three independent experiments.
Fig. 8. Induction of multinucleated giant cells in primary rhesus macrophages infected with recombinant SIV viruses. Shown are multinucleated giant cells on day 7
post-infection in rhesus MDM cultures infected with 10 ng of p27 of the indicated SIV viruses.
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(Edmonson et al., 1998), suggesting their importance for in vivo
infection. Removal of glycans at positions analogous to N173 or
N481 in HIV or SIV reduced infectivity in prior studies (Lee et al.,
1992; Pikora et al., 2005). Consistent with these ﬁndings, removal
of N173 and N481 reduced infectivity of 239/251 viruses in
TZM-BL cells, but enhanced viral replication in macrophages
in the present study. Viruses lacking these two N-glycosylation
sites may be less efﬁcient for cell-free infection, but may be
more efﬁcient at mediating fusion and cell-to-cell transmission
with low CD4 cells, thereby enhancing replication in macrophages
(Yen et al., 2014). These phenotypes might be strain-dependent,
since the macrophage-tropic SIVmac316 clone expresses N173
and N481.
N173 and N481 enhanced neutralization resistance of 239/251
SIV viruses. This ﬁnding is consistent with previous studies
showing that glycosylation sites, particularly those located in the
V1/V2 regions, contribute to neutralization resistance against
antiserum and multiple antibodies targeting a broad range of
epitopes (Chackerian et al., 1997; Johnson et al., 2003b; Pikora et
al., 2005; Sagar et al., 2006). Increased neutralization resistance to
monoclonal antibodies targeting CD4 binding site and V3 loop
suggests that N-glycans at these positions may modulate the
structure or accessibility of these epitopes. Indeed, previous
studies showed that loss of the N160 N-glycosylation site in HIV
Env (analogous to N173 in SIV) impaired CCR5 usage in a cell–cell
fusion assay (Ogert et al., 2001). Furthermore, N160 is a critical
residue in HIV gp120 for recognition and binding of a broadly
neutralizing antibody, PG9 (McLellan et al., 2011). The recent
ﬁnding that antibodies targeting the V2 region were the only
variable correlating with protection in the RV144 vaccine trial
highlight the importance of V2 as an immunogenic epitope
(Haynes et al., 2012; Rolland et al., 2012). The N173 glycan may
shield these epitopes from antibody recognition, and thereby
enhance neutralization resistance. 239/251 NN viruses generated
in PBMC were more neutralization resistant than those generated
in 293T cells, consistent with previous studies indicating that
gp120 glycosylation is dependent on the cellular source of viruses
(Lin et al., 2003; Willey et al., 1996). These ﬁnding suggest that
N173 may be an important determinant of neutralization sensi-
tivity for HIV and SIV infections. Further studies are required to
address this question and dissect individual roles of N173 and
N481 in determining neutralization sensitivity.
The association between neutralization sensitivity and SIV
macrophage tropism demonstrated in the present study and prior
studies may have different consequences for pathogenesis in the
periphery versus the CNS. In particular, strong neutralizing anti-
body responses in the periphery are expected to inhibit these
strains, while lower levels of neutralizing antibodies in the CNS
may allow them to replicate and persist in this compartment.
In conclusion, we characterized a unique macrophage-tropic
SIV Env variant from early stage infection that is closely related to
sequences in brain from several animals with neurological disease,
and identiﬁed novel determinants of SIV macrophage tropism and
neutralization sensitivity. The ﬁndings suggest that macrophage-
tropic SIV viruses capable of establishing persistent viral reservoirs
in macrophages in brain and other tissues can be present in blood
during early infection. Furthermore, the replication-competent
SIVmac251 clones described in this study replicate well in both
T-cells and macrophages, and are closely related to sequences not
only in brain, but also in non-brain tissues such as lymph node and
bone marrow, suggesting they will be useful for non-human
primate studies on HIV/SIV macrophage-related pathogenesis,
persistence and eradication of viral reservoirs, and vaccine
development.
Materials and methods
Isolation of SIV sequence variants from SIVmac251-infected rhesus
macaques
SIV gp120 sequence variants were cloned and sequenced from
archived samples stored at 80 1C, available from previous studies
of SIVmac251-infected rhesus macaques (Orandle et al., 2002;
Williams et al., 2002, 2001) (Table 1). Four macaques (Group I)
were infected with SIVmac251 stock from the Desrosiers lab; two
were inoculated intravenously and two intravaginally. The gp120
region was ampliﬁed by bulk PCR from genomic DNA of PBMC at
two weeks post-infection (p.i.). Four macaques (Group II) were
inoculated intravenously with 20 ng p27 of SIVmac251; two with
Table 3
Neutralization sensitivity proﬁle of replication-competent recombinant SIV viruses generated in 293 T cells.
Viruses
SIV251 antiserum SIV239 antiserum 5B11 7D3 36D5
IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
SIVmac239 <100 <100 <100 <100 <100 <100 <100 <100 <100 <100
SIVmac316 622542 126456 288437 104103 444272 518 537622 <100 107991 7401
desiv147c#4 626748 131824 276853 62275 570 <100 7330 <100 39535 1707
239/251 WT 192810 <100 145862 <100 343764 <100 10294 <100 30746 <100
239/251 WT NN 562 <100 <100 <100 447 <100 <100 <100 <100 <100
239/251 V2C3 68476 9134 39471 6469 34679 <100 477384 <100 27878 <100
239/251 V2C3 NN 2753 <100 24312 <100 146 <100 38502 <100 <100 <100
239/251 V2V3C3 189907 44743 119171 26760 169195 654 713938 118419 31203 <100
239/251 V2V3C3 NN 133147 101 72208 <100 75038 <100 502726 <100 690 <100
color code: <100
100 - 1000
1000 - 10000
>10000
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stock provided by the Desrosiers lab (the same virus stock used to
infect Group I) and two with stock provided by the Letvin lab.
Frozen brain tissue, lymph node, and bone marrow samples were
obtained at autopsy after these four animals died with AIDS, and
the gp120 region was ampliﬁed by bulk PCR from genomic DNA
isolated from these tissue samples. The ampliﬁed viral DNA
was cloned into a TOPO vector for sequencing, and the gp120
amino acid sequences were aligned and analyzed using BioEdit
and Clustal W.
Construction of recombinant Envs and viruses
Amino acid variants in the V1–V3 and C3 regions with shared
identity between the early variant in blood, desiv147#4, and the
gp120 consensus sequence of late variants in brain, were intro-
duced individually or in combination into SIVmac251 Env (SIV-
mac251BK28 clone) by site-directed mutagenesis. gp120 and the N-
terminus of gp41 (residues 1 to 213) of all recombinant Envs were
then sub-cloned into pSIVΔgpv (provided by Joseph Sodroski)
(Marcon and Sodroski, 1997) using restriction sites AfeI and NheI
to generate Env clones, or into 239-FL plasmid (Bixby et al., 2010)
using restriction sites BstBI and NheI to generate full-length
replication-competent proviruses. The gene fragment containing
desiv147c#4 Env was synthesized by GenScript Inc. and cloned
into pSIVΔgpv or 293-FL provirus as described above.
Env expression and cell–cell fusion assays
Recombinant Envs were expressed by transfecting 293T cells
with pSIVΔgpv, and Env expression examined by western blot-
ting of cell lysates. For cell–cell fusion assays, 293T cells co-
transfected with pSIVΔgpv and pLTR-Tat, a Tat expressing plas-
mid, were incubated with Cf2-luc cells (Etemad-Moghadam et al.,
2000) transiently expressing rhesus CD4 and CCR5. Expression of
the luciferase reporter gene in Cf2-luc cells is under the control of
HIV-1 LTR. After 8 h of co-incubation, cells were lysed and
luciferase activity was quantiﬁed as an indication of cell–cell
fusion.
Virus production and infectivity
Replication-competent viruses were generated by transfecting
293T cells with full-length provirus. For infection of TZM-BL cells,
replication-competent viruses were incubated with cells in the
presence of 15 mg/ml of DEAE-dextran. Two days p.i., luciferase
activity in cell lysates was measured. Viruses used for infection
Fig. 9. Macrophage tropism of recombinant SIV is associated with neutralization sensitivity to SIV251 antiserum, SIV 239 antiserum, 36D5 (anti-V3), and 5B11 (anti-CD4
binding site). The relationship between SIV replication in macrophages and neutralization sensitivity was analyzed by Spearman correlation. Replication in macrophages was
expressed as SIV p27 antigen concentration in cell culture supernatants at 10 days post-infection (Fig. 7B). Neutralization sensitivity was expressed as the reciprocal dilution
required for achieving 50% inhibition of infection with the no serum control.
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were normalized by reverse transcriptase activity or p27 antigen
concentration (ELISA from Advanced Bioscience Laboratories, Inc.,
Kensington, MD). Assays were performed in duplicate wells in 96-
well plates. For PBMC-derived viruses, viruses produced in 293T
cells were passaged in rhesus macaque PBMC for 5 days. After ﬁve
days of incubation, residual 293T-derived viruses were removed
by washing, and viruses generated in PBMC were harvested on
Day 7, 9, and 11 post-infection.
Fig. 10. Replication of PBMC-derived recombinant SIV viruses in primary rhesus macaque PBMC (A) and MDM (B). Viral replication was quantiﬁed in rhesus PBMC and MDM
infected with 2 ng p27 of the indicated PBMC-derived viruses by measuring SIV p27 antigen concentration in cell cultures supernatants by ELISA. Data in each panel are from
a single experiment, with viral replication of the panel of mutants examined in cells from the same animal donor. Values shown are means of duplicate wells.
Table 4
Neutralization sensitivity proﬁle of replication-competent recombinant SIV viruses generated in PBMC.
Viruses
SIV251 antiserum SIV239 antiserum 5B11 7D3 36D5
IC IC IC IC IC IC IC IC IC IC
SIVmac239 <100 <100 <100 <100 <100 <100 <100 <100 158 <100
SIVmac316 629106 132455 609154 115496 129037 156 752972 418318 166164 7959
desiv147c#4 627934 134022 296499 103497 101 <100 7512 <100 131625 3159
239/251 WT 513696 <100 219312 <100 133481 <100 601386 <100 7708 118
239/251 WT NN <100 <100 <100 <100 <100 <100 <100 <100 144 103
239/251 V2C3 110632 <100 35489 <100 1840 <100 470150 <100 9992 138
239/251 V2C3 NN <100 <100 <100 <100 <100 <100 <100 <100 198 107
color code: <100
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Neutralization assays
Viruses were pre-incubated with serial dilutions of heat-
inactivated SIVmac251 antiserum (NIH AIDS Research and Refer-
ence Reagent Program), SIVmac239 antiserum, or mouse ascites
containing SIV monoclonal antibodies (Edinger et al., 2000) at
37 1C for one hour. After pre-incubation, TZM-BL cells were added
with DEAE-dextran (ﬁnal concentration 15 μg/ml). Two days
later, cells were lysed and luciferase activity was measured.
Assays were performed in duplicate wells in 96-well plates.
Results are presented as IC50 and IC90, the reciprocal dilution of
antiserum or ascites required for achieving 50% and 90% inhibi-
tion of infection, respectively, relative to no serum or no ascites
controls.
Viral replication in PBMC and MDM
PBMC were isolated from rhesus macaque peripheral blood
(New England Primate Research Center) by Histopaque (Sigma)
density centrifugation and activated in RPMI 1640 supplemented
with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin
(P/S), 20 U/ml IL-2 and 1 μg/ml PHA-P for 3 days. Activated PBMC
were then maintained in RPMI supplemented with 10% FBS, 1% P/S
and 20 U/ml IL-2 and infected with replication-competent viruses.
Three hours p.i., viruses were removed by washing cells three
times with RPMI. To obtain MDM, PBMC were cultured in RPMI
containing 15% FBS, 10% human serum type AB, 1% P/S and 20 ng/
ml M-CSF for ﬁve days. Non-adherent cells were then removed by
washing three times with RPMI. Adherent cells were cultured in
RPMI supplemented with 15% FBS, 5% human serum type AB, 1% P/S
and 20 ng/ml M-CSF for two additional days before infection. For
infection, virus stocks were cultured with MDM for 24 h and then
removed by washing once with RPMI. Culture supernatant was
collected twice a week and p27 concentration was quantiﬁed by
ELISA (Advanced Bioscience Laboratories, Inc., Kensington, MD).
Assays were performed in duplicate wells in 96-well plates.
Sequences
All gp120 sequences were deposited in GenBank (accession
numbers JN376087 to JN376124).
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